Health & Medicine Immune markers of post vaccination syndrome indicate future research directions
A small number of people report chronic symptoms after receiving COVID-19 shots. A new study provides clues for further research.
Feb 19, 2025 5 min read By Mallory Locklear
AI-generated image and Adobe Stock, created and edited by Michael S. Helfenbein
Listen to this story 6:23
COVID-19 vaccines have been instrumental in reducing the impact of the pandemic, preventing severe illness and death, and they appear to protect against long COVID. However, some individuals have reported chronic symptoms that developed soon after receiving a COVID-19 vaccine. This little-understood, persistent condition, referred to as post-vaccination syndrome (PVS), remains unrecognized by medical authorities, and little is known about its biological underpinnings.
In a new study, Yale researchers have taken initial steps to characterize this condition, uncovering potential immunological patterns that differentiate those with PVS from others. The findings are early and require further confirmation but may eventually guide strategies to help affected individuals.
“This work is still in its early stages, and we need to validate these findings,” said Akiko Iwasaki, Sterling Professor of Immunobiology at Yale School of Medicine (YSM) and co-senior author of the study published Feb. 19 as a preprint on MedRxiv. “But this is giving us some hope that there may be something that we can use for diagnosis and treatment of PVS down the road.”
Some of the most common chronic symptoms of PVS include exercise intolerance, excessive fatigue, brain fog, insomnia, and dizziness. They develop shortly after vaccination, within a day or two, can become more severe in the days that follow, and persist over time. More studies are needed to understand the prevalence of PVS.
“It’s clear that some individuals are experiencing significant challenges after vaccination. Our responsibility as scientists and clinicians is to listen to their experiences, rigorously investigate the underlying causes, and seek ways to help,” said Harlan Krumholz, the Harold H. Hines, Jr. Professor of Medicine (Cardiology) at YSM and co-senior author of the study.
Data for the study came from Yale’s Listen to Immune, Symptom, and Treatment Experiences Now (LISTEN) Study, through which researchers aim to better understand long COVID and PVS. For the new study, researchers included data from 42 LISTEN participants who reported symptoms of PVS and 22 individuals who did not report any PVS symptoms after receiving a COVID-19 vaccination.
From participants’ blood samples, the researchers looked for immune features that were different between the two groups. They found several differences in immune cell populations; those with PVS had lower levels of effector CD4+ T cells and higher levels of TNF-alpha+ CD8 T cells — both are types of white blood cells — among other differences.
There were also differences in the levels of antibodies that the body uses to target SARS-CoV-2. Participants with PVS who had never contracted COVID-19 had lower levels of antibodies against the SARS-CoV-2 spike protein than control participants, likely because they tended to have fewer vaccine doses than individuals without PVS. Fewer vaccine doses and no viral infection means the body’s immune system has had little opportunity to develop a defense to the virus, said the researchers.
When the researchers measured levels of SARS-CoV-2 spike protein — the part of the virus that enables it to penetrate and infect host cells and what COVID-19 vaccines use to trigger immune responses against the virus — they found that some individuals with PVS, even those without evidence for infection, had higher levels of spike protein than controls. Typically spike protein can be detected for a few days after vaccination, but some participants with PVS had detectable levels more than 700 days after their last vaccination. Persistent spike protein has been associated with long COVID as well.
“That was surprising, to find spike protein in circulation at such a late time point,” said Iwasaki. “We don’t know if the level of spike protein is causing the chronic symptoms, because there were other participants with PVS who didn’t have any measurable spike protein. But it could be one mechanism underlying this syndrome.”
Krumholz explained that PVS might be similar to how different infections can cause chronic symptoms through distinct biological pathways. “One person might develop chronic symptoms due to immune dysregulation, while another experiences lingering effects from viral reactivation,” he said. “We need to map these different pathways carefully to understand what is happening in each case. This work is just beginning, and further studies are essential to guide diagnosis and treatment.”
Going forward, the researchers want to further validate these findings in a larger group of people “This is far from a final answer on PVS,” said Iwasaki.
They’re also investigating several possible drivers of PVS. Along with spike protein persistence, the researchers are assessing the contributions of autoimmunity, tissue damage, and Epstein-Barr Virus (EBV) reactivation. In the study, individuals with PVS were more likely than those without the syndrome to have evidence of reactivated EBV, which is the most common cause of infectious mononucleosis, also known as “mono.”
A deeper understanding of PVS and its drivers could lead to better vaccines that have fewer side effects, effective methods for diagnosing the syndrome, and targets for treatment, said the researchers.
“For instance, if we can determine why spike protein is persisting for as long as it is in some people, maybe we can remove it — with monoclonal antibodies, for example — and maybe that could help reduce PVS symptoms,” said Iwasaki.
Iwasaki is also a professor of dermatology and of molecular, cellular, and developmental biology in Yale’s Faculty of Arts and Sciences, a professor of epidemiology at Yale School of Public Health, and an investigator of the Howard Hughes Medical Institute.
“We’re only just starting to make headway in understanding PVS,” said Krumholz. “Every medical intervention carries some risk, and it’s important to acknowledge that adverse events can occur with vaccines. Our focus must remain on understanding what these people are experiencing through rigorous science and addressing the needs of those affected with compassion and an open mind.”
文章第一句： COVID-19 vaccines have been instrumental in reducing the impact of the pandemic, preventing severe illness and death, and they appear to protect against long COVID.
Yale的这种开场白只是一种为了cover MSM ass的话术而已。重要的信息是在那个“however”之后。文章里说，有些人体内的Spike protein 在打针后的700天后还可以被测出。而persistant spike protein has been associated with long covid as well.
这些还只是目前阶段已知的信息而已，就已经“surprising" 了。那将来还不知道有多少surprises了，are you ready? 一句话，你再怎末洗白，都改变不了一个事实，这是一个实验型的medical intervention. 目的是什么，估计再给些时间，就可以看得更清楚了。
Vaccine victims left disabled after taking Covid jab react to bombshell Yale study that found shots cause extreme body changes在全家人包括医学生儿子的压力下，最终很不情愿地打了。因为不打疫苗可能连家都回不了。
哪天就挂了，，，
Enough said
Health & Medicine Immune markers of post vaccination syndrome indicate future research directions
A small number of people report chronic symptoms after receiving COVID-19 shots. A new study provides clues for further research.
Feb 19, 2025 5 min read By Mallory LocklearAI-generated image and Adobe Stock, created and edited by Michael S. Helfenbein
COVID-19 vaccines have been instrumental in reducing the impact of the pandemic, preventing severe illness and death, and they appear to protect against long COVID. However, some individuals have reported chronic symptoms that developed soon after receiving a COVID-19 vaccine. This little-understood, persistent condition, referred to as post-vaccination syndrome (PVS), remains unrecognized by medical authorities, and little is known about its biological underpinnings.
In a new study, Yale researchers have taken initial steps to characterize this condition, uncovering potential immunological patterns that differentiate those with PVS from others. The findings are early and require further confirmation but may eventually guide strategies to help affected individuals.
“This work is still in its early stages, and we need to validate these findings,” said Akiko Iwasaki, Sterling Professor of Immunobiology at Yale School of Medicine (YSM) and co-senior author of the study published Feb. 19 as a preprint on MedRxiv. “But this is giving us some hope that there may be something that we can use for diagnosis and treatment of PVS down the road.”
Some of the most common chronic symptoms of PVS include exercise intolerance, excessive fatigue, brain fog, insomnia, and dizziness. They develop shortly after vaccination, within a day or two, can become more severe in the days that follow, and persist over time. More studies are needed to understand the prevalence of PVS.
“It’s clear that some individuals are experiencing significant challenges after vaccination. Our responsibility as scientists and clinicians is to listen to their experiences, rigorously investigate the underlying causes, and seek ways to help,” said Harlan Krumholz, the Harold H. Hines, Jr. Professor of Medicine (Cardiology) at YSM and co-senior author of the study.
Data for the study came from Yale’s Listen to Immune, Symptom, and Treatment Experiences Now (LISTEN) Study, through which researchers aim to better understand long COVID and PVS. For the new study, researchers included data from 42 LISTEN participants who reported symptoms of PVS and 22 individuals who did not report any PVS symptoms after receiving a COVID-19 vaccination.
From participants’ blood samples, the researchers looked for immune features that were different between the two groups. They found several differences in immune cell populations; those with PVS had lower levels of effector CD4+ T cells and higher levels of TNF-alpha+ CD8 T cells — both are types of white blood cells — among other differences.
There were also differences in the levels of antibodies that the body uses to target SARS-CoV-2. Participants with PVS who had never contracted COVID-19 had lower levels of antibodies against the SARS-CoV-2 spike protein than control participants, likely because they tended to have fewer vaccine doses than individuals without PVS. Fewer vaccine doses and no viral infection means the body’s immune system has had little opportunity to develop a defense to the virus, said the researchers.
When the researchers measured levels of SARS-CoV-2 spike protein — the part of the virus that enables it to penetrate and infect host cells and what COVID-19 vaccines use to trigger immune responses against the virus — they found that some individuals with PVS, even those without evidence for infection, had higher levels of spike protein than controls. Typically spike protein can be detected for a few days after vaccination, but some participants with PVS had detectable levels more than 700 days after their last vaccination. Persistent spike protein has been associated with long COVID as well.
“That was surprising, to find spike protein in circulation at such a late time point,” said Iwasaki. “We don’t know if the level of spike protein is causing the chronic symptoms, because there were other participants with PVS who didn’t have any measurable spike protein. But it could be one mechanism underlying this syndrome.”
Krumholz explained that PVS might be similar to how different infections can cause chronic symptoms through distinct biological pathways. “One person might develop chronic symptoms due to immune dysregulation, while another experiences lingering effects from viral reactivation,” he said. “We need to map these different pathways carefully to understand what is happening in each case. This work is just beginning, and further studies are essential to guide diagnosis and treatment.”
Going forward, the researchers want to further validate these findings in a larger group of people “This is far from a final answer on PVS,” said Iwasaki.
They’re also investigating several possible drivers of PVS. Along with spike protein persistence, the researchers are assessing the contributions of autoimmunity, tissue damage, and Epstein-Barr Virus (EBV) reactivation. In the study, individuals with PVS were more likely than those without the syndrome to have evidence of reactivated EBV, which is the most common cause of infectious mononucleosis, also known as “mono.”
A deeper understanding of PVS and its drivers could lead to better vaccines that have fewer side effects, effective methods for diagnosing the syndrome, and targets for treatment, said the researchers.
“For instance, if we can determine why spike protein is persisting for as long as it is in some people, maybe we can remove it — with monoclonal antibodies, for example — and maybe that could help reduce PVS symptoms,” said Iwasaki.
Iwasaki is also a professor of dermatology and of molecular, cellular, and developmental biology in Yale’s Faculty of Arts and Sciences, a professor of epidemiology at Yale School of Public Health, and an investigator of the Howard Hughes Medical Institute.
“We’re only just starting to make headway in understanding PVS,” said Krumholz. “Every medical intervention carries some risk, and it’s important to acknowledge that adverse events can occur with vaccines. Our focus must remain on understanding what these people are experiencing through rigorous science and addressing the needs of those affected with compassion and an open mind.”
文章第一句：
COVID-19 vaccines have been instrumental in reducing the impact of the pandemic, preventing severe illness and death, and they appear to protect against long COVID.
翻译成容易懂的中文是这样的：
COVID-19 疫苗在减少疫情影响、预防重病和死亡方面发挥了重要作用，而且似乎可以预防长期 COVID。
先看到成绩，然后再说缺点，是这个意思吧？
对照组，你又如何知道针可以减重症？ 拿什么做对比？
Yale的这种开场白只是一种为了cover MSM ass的话术而已。重要的信息是在那个“however”之后。文章里说，有些人体内的Spike protein 在打针后的700天后还可以被测出。而persistant spike protein has been associated with long covid as well.
这些还只是目前阶段已知的信息而已，就已经“surprising" 了。那将来还不知道有多少surprises了，are you ready? 一句话，你再怎末洗白，都改变不了一个事实，这是一个实验型的medical intervention. 目的是什么，估计再给些时间，就可以看得更清楚了。
什么是无症状 COVID-19？
新冠却没有症状，所以不自知。那么这个20%的统计数据是哪里来的？
哦对了，他们不是还改了疫苗的定义吗？好了不多说了。大家多多保重。
想劝劝“别打那么多拉， 3针足够了”， 刚开口就被堵回来“3个月后失效，感染新冠怎么办？”。我立即shut up.
各人心中的上帝不一样， 我有那闲工夫不如睡觉去，还能增强免疫力。